Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Brendan L. Hagerty

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2805-4636; OpenAlex author ID A5061712164. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 3

  1. Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.27803↗
  2. High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis. Co-author PMID 37818071↗
  3. Molecular mediators of peritoneal metastasis in pancreatic cancer. First author DOI 10.1007/s10555-020-09924-4↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masanori Oshi · 1 shared paper, 2023 · strength 0.26
  2. Kazuaki Takabe · 1 shared paper, 2023 · strength 0.26
  3. Itaru Endo · 1 shared paper, 2023 · strength 0.26
  4. Leonid Cherkassky · 1 shared paper, 2024 · strength 0.23
  5. Zachary E. Stiles · 1 shared paper, 2024 · strength 0.23
  6. Christos K Fountzilas · 1 shared paper, 2024 · strength 0.23
  7. Leela Rani Avula · 1 shared paper, 2020 · strength 0.19
  8. Christine Alewine · 1 shared paper, 2020 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.